安剛，中國醫學科學院血液病醫院（中國醫學科學院血液學研究所）淋巴瘤診療中心，主任醫師、淋巴瘤診療中心主任助理、多發性骨髓瘤組長、博士、副教授、博士生導師、實驗血液學國家重點實驗室PI。 2020年度中國腫瘤青年科學家獎獲得者，天津市131創新型人才培養工程第一層次人才，天津市衛生計生行業高層次人才選拔培養工程青年醫學新銳。主要從事淋巴瘤和多發性骨髓瘤（MM）的臨床和基礎研究。
基本介紹
個人經歷,擅長領域,學術任職,科研成果,發表文章,獲獎情況,出診時間,
個人經歷
2003年畢業於山東醫科大學臨床醫學專業，2003-2006於中國醫學科學院血液病醫院(血液學研究所)做住院醫師。2013年11月-2016年7月在哈佛大學Dana-Farber癌症學院進行博士後研究，主要研究方向為多發性骨髓瘤免疫微環境及靶向治療。
擅長領域
漿細胞疾病（多發性骨髓瘤、澱粉樣變性、罕見漿細胞疾病等）及淋巴瘤（瀰漫大B細胞淋巴瘤、濾泡性淋巴瘤、慢性淋巴細胞白血病、邊緣區淋巴瘤、霍奇金淋巴瘤、外周T細胞淋巴瘤等）的診治。
學術任職
中國抗癌協會青年理事
CSCO多發性骨髓瘤專家委員會秘書長
中國抗癌協會血液淋巴腫瘤第二屆青委副主任委員
中華醫學會血液學分會第十一屆委員會青委會委員
中國抗癌協會轉化醫學委員會委員
中國多發性骨髓瘤研究聯盟委員秘書
科研成果
以第一作者或通訊作者發表多發性骨髓瘤相關SCI論文30餘篇，分別發表在Blood、Leukemia、Clinical Cancer Research、Haematologica、Blood Advances等；總影響因子200餘分。主編專著一部《內科疑難病例-血液分冊》(人民衛生出版社ISBN:9787117131599)，副主譯《威廉士血液學手冊第9-10版》（科學出版社ISBN: 9787030637680）。主持國家自然基金3項，作為主要執行人參與國家自然基金國際合作項目。研發克隆演變檢測試劑盒，並獲得專利。
發表文章
[1] An G, Acharya C, Feng X, Wen K, Zhong M, Zhang L, Munshi NC, Qiu L*, Tai YT, Anderson KC*. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood. 2016 Sep 22;128(12):1590-603.
[2] An G(*), Yan Y(co-first author), Xu Y, Mao X, Liu J, Fan H, Wang Q, Du C, Li Z, Yi S, Lv R, Deng S, Sui W, Fu M, Hao M, Huang W, Zou D, Zhao Y, Yuan C, Du X, Wang J, Cheng T, Tai YT, Munshi NC(*), Qiu L(*). Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020 Feb;34(2):578-588.
[3] An G, Li Z, Tai Y, Acharya C, Li Q, Qin X, Yi S, Xu Y, Fen X, Li C, Zhao J, Shi L, Zang M, Deng S, Sui W, Hao M, Zou D, Zhao Y, Qi J, Cheng T, Ru K, Wang J, Qiu L*, Anderson K*. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin Cancer Res. 2015 May 1;21(9):2148-56
[4] Fan Hui, Xu J, Fan H, Li L, Cui J, Du C, Deng S, Sui W, Xu Y, Hao M, Anderson KC, Zou D(*), Qiu L(*), An G(*). Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM). Clinical Cancer Research 2023
[5] An G, Zhou D, Cheng S, Zhou KS, Li J, Zhou J, Xie L, Jin J, Zhong LY, Yan L, Guo H, Du C, Zhong J, Yu Y, Wu B, Qiu L. A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. Clin Cancer Res. 2021 Oct 15;27(20):5492-5501.
[6] Yan W, Xu J, Fan H, Li L, Cui J, Du C, Deng S, Sui W, Xu Y, Hao M, Anderson KC, Zou D(*), Qiu L(*), An G(*). Development and validation of an individualized and weighted myeloma prognostic score system (MPSS) in patients with newly diagnosed multiple myeloma. American Journal of hematology 2023
[7] An G, Xu Y, Shi L, Shizhen Z, Deng S, Xie Z, Sui W, Zhan F, Qiu L*. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no prognostic value. Haematologica. 2014 Feb;99(2):353-9.
[8] Cui J, Lv R, Yu T, Yan W, Xu J, Fan H, Li L, Liu Y, Du C, Deng S, Sui W, Xu Y, Yi S, Zou D, Qiu L, An G(*). Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma. Haematologica. 2023 Aug 3. doi: 10.3324/haematol.2023.283533.
[9] Xiaoyan Qu #, Gang An #, Weiwei Sui, Tingyu Wang, Xian Zhang, Junfang Yang, Yan Zhang, Lu Zhang, Dan Zhu, Jiaqi Huang, Shigui Zhu, Xin Yao, Jing Li, Chengxiao Zheng, Kevin Zhu, Yutian Wei, Xiaoteng Lv, Liping Lan, Yihong Yao, Daobin Zhou, Peihua Lu, Lugui Qiu, Jianyong Li. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. J Immunother Cancer. 2022 Sep;10(9):e005145.
[10] Yan Y, Mao X, Liu J, Fan H, Du C, Li Z, Yi S, Xu Y, Lv R, Liu W, Deng S, Sui W, Wang Q, Zou D, Wang J, Cheng T, Zhan F, Tai YT, Yuan C, Du X, Qiu L(*), Anderson KC(*), An G(*). The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Adv. 2019 Oct 8;3(19):2895-2904.
[11] Yan Y, Qin X, Liu J, Fan H, Yan W, Liu L, Du C, Yu Z, Xu Y, Hao M, Deng S, Sui WW, Lv R, Liu W, Wang Q, Zou D, Hu L, Wang J, Tai YT, Anderson KC, Zhang L, Cheng T, Zetterberg A, Munshi N C (*), Qiu L(*), An G(*).Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single cell level by QM-FISH. Blood Adv. 2022 Jan 25;6(2):441-451.
[12] Liu J, Yan W, Fan H, Xu J, Li L, Du C, Mao X, Yan Y, Xu Y, Sui W, Deng S, Yi S, Anderson KC, Qiu L, Zou D, An G(*). Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment. Cancer Res Commun. 2023 Sep 6;3(9):1770-1780.
[13] Yan W, Xu J, Fan H, Li L, Cui J, Du C, Deng S, Sui W, Xu Y, Hao M, Anderson KC, Zou D(*), Qiu L(*), An G(*). Early relapse within 18 months (ER18) is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma. Cancer. 2023 Oct 17. doi: 10.1002/cncr.35056.
獲獎情況
2018年度天津市衛生計生行業高層次人才選拔培養工程青年醫學新銳；
2020年度天津市“131”創新型人才培養工程第一層次人才；
2020年度中國腫瘤青年科學家獎；
高等學校科學技術獎二等獎一項；
天津市科技進步一等獎。
出診時間
每周二上午，中國醫學科學院血液病醫院本部；
每周一下午，中國醫學科學院血液病醫院團泊院區。
